Search Results
You are looking at 1 - 3 of 3 items for
- Author: Margaret de Castro x
- Refine by access: All content x
Endocrinology Unit, Cell Pathology Laboratory, Endocrinology Unit, Endocrinology Unit, Endocrinology Laboratory, Clementino Fraga Filho University Hospital
Search for other papers by Leandro Kasuki in
Google Scholar
PubMed
Endocrinology Unit, Cell Pathology Laboratory, Endocrinology Unit, Endocrinology Unit, Endocrinology Laboratory, Clementino Fraga Filho University Hospital
Search for other papers by Leonardo Vieira Neto in
Google Scholar
PubMed
Search for other papers by Luiz Eduardo A Wildemberg in
Google Scholar
PubMed
Search for other papers by Leandro Machado Colli in
Google Scholar
PubMed
Search for other papers by Margaret de Castro in
Google Scholar
PubMed
Search for other papers by Christina M Takiya in
Google Scholar
PubMed
Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
Search for other papers by Régia Caroline Peixoto Lira in
Google Scholar
PubMed
Search for other papers by Paola Fernanda Fedatto in
Google Scholar
PubMed
Search for other papers by David Santos Marco Antonio in
Google Scholar
PubMed
Search for other papers by Letícia Ferro Leal in
Google Scholar
PubMed
Search for other papers by Carlos Eduardo Martinelli in
Google Scholar
PubMed
Search for other papers by Margaret de Castro in
Google Scholar
PubMed
Search for other papers by Silvio Tucci in
Google Scholar
PubMed
Search for other papers by Luciano Neder in
Google Scholar
PubMed
Search for other papers by Leandra Ramalho in
Google Scholar
PubMed
Search for other papers by Ana Luiza Seidinger in
Google Scholar
PubMed
Search for other papers by Izilda Cardinalli in
Google Scholar
PubMed
Search for other papers by Maria José Mastellaro in
Google Scholar
PubMed
State University of Campinas (UNICAMP), CampinasSão Paulo, Brazil
Search for other papers by José Andres Yunes in
Google Scholar
PubMed
State University of Campinas (UNICAMP), CampinasSão Paulo, Brazil
Search for other papers by Silvia Regina Brandalise in
Google Scholar
PubMed
Search for other papers by Luiz Gonzaga Tone in
Google Scholar
PubMed
Search for other papers by Sonir Roberto Rauber Antonini in
Google Scholar
PubMed
Search for other papers by Carlos Alberto Scrideli in
Google Scholar
PubMed
Deregulation of the IGF system observed in human tumors indicates a role in malignant cell transformation and in tumor cell proliferation. Although overexpression of the IGF2 and IGF1R genes was described in adrenocortical tumors (ACTs), few studies reported their profiles in pediatric ACTs. In this study, the IGF2 and IGF1R expression was evaluated by RT-qPCR according to the patient’s clinical/pathological features in 60 pediatric ACT samples, and IGF1R protein was investigated in 45 samples by immunohistochemistry (IHC). Whole transcriptome and functional assays were conducted after IGF1R inhibition with OSI-906 in NCI-H295A cell line. Significant IGF2 overexpression was found in tumor samples when compared with non-neoplastic samples (P<0.001), significantly higher levels of IGF1R in patients with relapse/metastasis (P=0.031) and moderate/strong IGF1R immunostaining in 62.2% of ACTs, but no other relationship with patient survival and clinical/pathological features was observed. OSI-906 treatment downregulated genes associated with MAPK activity, induced limited reduction of cell viability and increased the apoptosis rate. After 24h, the treatment also decreased the expression of genes related to the steroid biosynthetic process, the protein levels of the steroidogenic acute regulatory protein (STAR), and androgen secretion in cell medium, supporting the role of IGF1R in steroidogenesis of adrenocortical carcinoma cells. Our data showed that the IGF1R overexpression could be indicative of aggressive ACTs in children. However, in vitro treatments with high concentrations of OSI-906 (>1μM) showed limited reduction of cell viability, suggesting that OSI-906 alone could not be a suitable therapy to abolish carcinoma cell growth.
Search for other papers by Ana Carolina Bueno in
Google Scholar
PubMed
Search for other papers by Rui M P da Silva in
Google Scholar
PubMed
Search for other papers by Mônica F Stecchini in
Google Scholar
PubMed
Search for other papers by Junier Marrero-Gutiérrez in
Google Scholar
PubMed
Department of Computation and Mathematics, Faculty of Philosophy, Sciences and Letters at Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
Search for other papers by Danillo C de Almeida e Silva in
Google Scholar
PubMed
Search for other papers by Izilda Cardinalli in
Google Scholar
PubMed
Search for other papers by Carlos Alberto Scrideli in
Google Scholar
PubMed
Search for other papers by Thais Junqueira in
Google Scholar
PubMed
Search for other papers by Carlos A F Molina in
Google Scholar
PubMed
Search for other papers by Fernando Silva Ramalho in
Google Scholar
PubMed
Search for other papers by Silvio Tucci Jr in
Google Scholar
PubMed
Search for other papers by Fernanda Borchers Coeli-Lacchini in
Google Scholar
PubMed
Search for other papers by Ayrton Custodio Moreira in
Google Scholar
PubMed
Search for other papers by Leandra N Z Ramalho in
Google Scholar
PubMed
Search for other papers by Silvia Brandalise in
Google Scholar
PubMed
Search for other papers by José Andres Yunes in
Google Scholar
PubMed
Search for other papers by Margaret de Castro in
Google Scholar
PubMed
Search for other papers by Ricardo Zorzetto Nicoliello Vêncio in
Google Scholar
PubMed
Search for other papers by Sonir R R Antonini in
Google Scholar
PubMed
Children diagnosed with pediatric adrenocortical tumors (pACT) have variable outcomes, and, to date, the disease lacks robust prognostic biomarkers. The prognostic potential of tumor methylation has been demonstrated in several cancers. We aimed to evaluate the pACT methylation profile and its association with disease presentation and survival. In this cross-sectional study, we accessed the DNA methylation (MethylationEPIC Array, Illumina) of 57 primary pACT from Southeastern Brazil and the respective patients’ clinicopathological features. We also applied our analysis in an independent 48 pACT methylation dataset. Unsupervised learning whole-methylome analysis showed two groups with distinct methylation signatures: pACT-1 and pACT-2. Compared to pACT-2, pACT-1 tumors were enriched with higher methylation in CpG islands, mainly in gene promoter regions. The topmost hypermethylated gene in these samples was shown to be underexpressed. Patients in the pACT-1 group were older at diagnosis and were more likely to have carcinomas and nonlocalized/advanced and recurrent/metastatic disease. Univariate and bivariate regressions showed that pACT-1 methylation signature confers superior hazard ratio of disease progression and death than known prognostic features. The methylation groups had similar frequencies of germline mutations in the TP53 gene, including the regionally frequent p.R337H. Our analysis replication validated our findings and reproduced those recently described in pACT. We demonstrated the existence of different tumor methylation signatures associated with pACT presentation and clinical evolution, even in the context of germline TP53 mutations. Our data support tumor methylation profiling as a robust and independent prognostic biomarker for pACT and suggest a list of candidate genes for further validation.